DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

REGN·Regeneron Pharmaceuticals, Inc.

$.
+. (+.%)
High
$655.00
Open
$642.45
Market Cap
66.98B
52W High
$821.11
Low
$637.21
P. Close
$638.88
P/E
15.14
52W Low
$476.49
Fwd P/E
11.88
Mean Target
-
Technical Score (1D)
9
SELL
News Sentiment
45
MIXED
Regeneron Pharmaceuticals announced a significant $2.32 billion collaboration with Parabilis Medicines, aiming to develop novel therapeutics for previously "undruggable" protein targets by leveraging Parabilis' Helicon peptide platform. This strategic move expands Regeneron's pipeline into new therapeutic modalities and could unlock treatments for challenging diseases. However, recent developments cast a shadow, as Regeneron's Phase 3 trial for fianlimab+cemiplimab missed its primary progression-free survival endpoint. In response, Canaccord significantly reduced its price target for Regeneron to $875, while Wolfe Research also lowered its target, though both maintained Buy or Outperform ratings. Analysts are now highlighting the importance of commercial execution and potential catalysts expected in the second half of 2026. Investors will be watching for updates on the company's strategy to navigate these setbacks and capitalize on new pipeline opportunities.
Earnings Summary
Regeneron Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines for serious diseases, with a strong portfolio including treatments for eye conditions, atopic dermatitis, asthma, and various cancers. Operating within the biotechnology sector, Regeneron leverages its research and development capabilities to address unmet medical needs and explore advanced therapies. The company's recent performance shows a mixed trend in earnings per share (EPS) and revenue. In Q4 2025, Regeneron reported an EPS of $11.44, exceeding the estimate of $10.84, and revenue of $3.88 billion, slightly above the estimate of $3.87 billion. This followed a strong Q3 2025 where actual EPS of $11.83 beat the estimate of $9.64. However, Q1 2026 saw actual EPS of $9.47 fall short of the $8.90 estimate, despite revenue of $3.61 billion surpassing the $3.48 billion estimate. The preceding quarters also showed variability, with Q2 2025 EPS of $12.89 significantly beating the $8.44 estimate, while Q1 2025 EPS of $8.22 missed the $8.48 estimate. Historically, Regeneron has demonstrated a pattern of revenue growth, though EPS performance against estimates has been inconsistent, with several quarters beating expectations and others missing. For instance, Q4 2024 saw a substantial EPS beat ($12.07 actual vs. $11.19 estimate), while Q1 2025 marked a miss. Recent news highlights significant challenges, including a Phase 3 trial for fianlimab in melanoma not meeting its primary endpoint, leading to analyst downgrades and price target reductions. This setback, coupled with concerns about decelerating revenue growth and declining free cash flow margins, has put pressure on the stock. Investors will be watching for the company's strategic response to the trial outcome and any progress in new collaborations, such as the partnership with Parabilis Medicines, to navigate these headwinds and identify future growth drivers.

EPS

EstBeatMiss
$7.52$9.04$10.55$12.07$13.59Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$10.85 - -
Q1'26$8.90$9.47+6.4%
Q4'25$10.84$11.44+5.5%
Q3'25$9.64$11.83+22.7%
Q2'25$8.44$12.89+52.7%
Q1'25$8.48$8.22-3.0%

Revenue

EstBeatMiss
$2.9B$3.2B$3.5B$3.7B$4.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.9B - -
Q1'26$3.5B$3.6B+3.5%
Q4'25$3.9B$3.9B+0.4%
Q3'25 - $3.8B -
Q2'25 - $3.7B -
Q1'25 - $3.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

REGN Stock Snapshot

REGN is currently trading at $640.93, giving Regeneron Pharmaceuticals, Inc. a market cap of 66.98B and a P/E ratio of 15.1. Today's range spans $637.21–$655.00, with shares opening at $642.45 and moving up $2.05 (0.3%) from the prior close. DailyIQ's technical score sits at 9/100 (SELL) with a news sentiment reading of 45/100.

Over the past year REGN has traded between $476.49 and $821.11 - the current price is +34.5% off the 52-week low and -21.9% from the high.

Risk is elevated for Regeneron Pharmaceuticals, Inc. (REGN) right now - bearish technical setup (9/100, SELL), neutral sentiment (45/100), price $640.93 (in the middle of its 52-week range). The current P/E ratio stands at 15.1. At 66.98B in Healthcare market cap, the 52-week range of $476.49–$821.11 defines where structural demand might resurface - because at this capitalization tier, buyers don't disappear, they just move their bids to different price levels.

Analyst coverage for REGN becomes a double-edged factor in a SELL phase: at 66.98B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 9/100 technical reading and neutral sentiment (45/100) at $640.93 (in the middle of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $476.49–$821.11 range establishes where that repricing lands.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…